Partners Capital Investment Group, LLP I Mab Transaction History

Partners Capital Investment Group, LLP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$4.01 - $12.34 $887,517 - $2.73 Million	-221,326 Closed	0 $0
Q2 2022 Aug 15, 2022	BUY	$8.27 - $18.43 $206,559 - $460,326	24,977 Added 12.72%	221,326 $2.5 Million
Q1 2022 May 16, 2022	BUY	$12.54 - $46.93 $1.07 Million - $4.01 Million	85,380 Added 76.94%	196,349 $3.19 Million
Q4 2021 Feb 14, 2022	BUY	$45.28 - $74.5 $5.02 Million - $8.27 Million	110,969 New	110,969 $5.26 Million

15.5M

56.4K

5.8K

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $78.9M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

Get notified when there are updates to the investment portfolio of Partners Capital Investment Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Partners Capital Investment Group, LLP with notifications on news.